ENTASIS THERAPEUTICS, INC. Waltham, MA, USA
COMBINATION OF CEFPODOXIME PROXETIL WITH NOVEL ORAL BLI
Direct-Acting Small Molecule Therapeutic
Entasis’ anti-infective discovery platform has produced a pipeline of innovative preclinical and clinical programs which target Gram-negative bacterial infections. Entasis, in partnership with CARB-X, is addressing a significant unmet medical need: the lack of an oral therapy to treat multi-drug resistant Gram-negative bacterial infections, including those caused by carbapenem-resistant Enterobacteriaceae (CRE). Currently, many patients with CRE infections require hospitalization for intravenous therapy because antimicrobial resistance has rendered all available oral therapies ineffective. Entasis’ novel oral agent has the potential to reduce or eliminate the need for hospitalization.
Current Development Stage: Phase 1
CARB-X Investment: Initial investment of up to $2.1m with potential option payments up to $4.2m
Initial CARB-X Investment Date: April 1, 2017
Graduation Date: April 1, 2021